PEPFAR accused of

22 December 2006

A US campaigning organization has claimed that the US President's Emergency Plan for AIDS Relief is "too slow" to add generic antiretroviral drugs to its procurement lists for distribution to countries most affected by HIV/AIDS.

The Center for Public Integrity, a group opposed to corporate influence in politics, which is funded by Democratic Party supporters, has been running a campaign, titled Divine Intervention, against the Republican US President, George W Bush's $15.0-billion PEPFAR program. The CPI has calculated that only about 5% of the PEPFAR's budget for antiretrovirals, $15.0 million, was spent on generic drugs in 2004 and 2005.

The PEPFAR only purchases drugs that have been approved by the US Food and Drug Administration or been given tentative approval via an expedited review process. The CPI claims that the FDA had approved 26 generic ARVs for the aid program but that, in 2004, "almost all ARVs administered through the program were from well-known companies that make brand-name drugs." The group even suggests that the requirement that drugs be registered in recipient countries is a deliberate bureaucratic obstacle against generic drugmakers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight